TNF-alpha inhibitors remain the primary choice for psoriatic arthritis (PsA) after conventional DMARD failure, but competing biologics such as IL-17 inhibitors (Cosentyx, Taltz), IL-12/23…
Acute and chronic heart failure (HF) have distinct treatment pathways, and both are covered in this report. Although much progress has been made in the pharmacological management of HF, this…
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder associated with progressive inflammation and/or fibrosis of the lung tissue. The leading cause of the disorder is unknown. IPF…
TNF-alpha inhibitors (e.g., Remicade, Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while non-TNF biologics (i.e., Takeda’s Entyvio, a CAM…
The market for nonalcoholic steatohepatitis (NASH), a severe form of nonalcoholic fatty liver disease (NAFLD), has great untapped potential owing to the lack of approved treatment options and the…
Scleroderma, also known as systemic sclerosis (SSc), is a rare, progressive, and debilitating autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that…
Clarivate Epidemiology’s coverage of obstructive sleep apnea (OSA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Clarivate Epidemiology’s coverage of acute heart failure (AHF) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France…
Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States,…
Clarivate Epidemiology’s coverage of heart failure (HF) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed event rates of AHF…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key chronic heart failure patient populations, covering 171 countries…
Clarivate Epidemiology’s coverage of heart failure (HF) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed event rates of AHF…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key acute heart failure patient populations, covering 171 countries and…